STOCK TITAN
  1. Home
  2. SEC Filings
  3. VICR
  4. [144] VICOR CORP SEC Filing

VICR files Section 144 listing multiple 10b5-1 sales

VICR submitted a Section 144 notice listing proposed resales of Common stock and disclosing numerous 10b5-1 sale transactions by Patrizio Vincarelli and other holders.

Filing Impact
(Neutral)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
144

Rhea-AI Filing Summary

VICR submitted a Section 144 notice listing proposed resales of Common stock and disclosing numerous 10b5-1 sale transactions by Patrizio Vincarelli and other holders.

The filing lists multiple executed 10b5-1 sales with individual trades such as 20,000 shares on 06/09/2026 and 50,000 shares on 04/15/2026, each showing gross proceeds in dollars. The filing also lists 33,863,689 shares outstanding as of 06/10/2026 as a baseline figure.

Insights

Section 144 notice documents proposed resale activity and records many rule-based 10b5-1 sales.

The filing catalogs multiple resale entries attributed to Patrizio Vincarelli and institutional holders, listing trade dates, share counts, and gross dollar amounts for each sale. These are presented as executed transactions under trading arrangements.

Cash‑flow treatment and whether the issuer receives proceeds are not stated in the excerpt; subsequent filing details would clarify transfer mechanics and any lockup or registration timing constraints.

Sample trade 20,000 shares sale dated 06/09/2026
Sample trade 50,000 shares sale dated 04/15/2026
Gross proceeds example $5,599,845.00 proceeds for 20,000 shares on 06/09/2026
Shares outstanding 33,863,689 shares as of 06/10/2026
Founders shares listing 20,000 Founders Shares dated 11/10/1981
10b5-1 regulatory
"10b5-1 Sales for PATRIZIO VINCIARELLI 25 Frontage Road"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
Section 144 regulatory
"144: Securities To Be Sold"
Founders Shares market
"Common | 11/10/1981 | Founders Shares"
Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.
Gross proceeds financial
"20000 | 5599845.00"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does VICR's Form 144 disclose about insider sales?
The Form 144 lists multiple proposed resales and executed trades, including 20,000 shares on 06/09/2026 and 50,000 shares on 04/15/2026. It shows trade dates, share counts, and gross proceeds for each transaction.

Who executed the majority of reported 10b5-1 sales in the VICR excerpt?
Many of the listed 10b5-1 sales are attributed to Patrizio Vincarelli, with repeated entries across March–June 2026 showing multiple trades of tens of thousands of shares and associated gross proceeds.

Does the filing state shares outstanding for VICR?
Yes, the excerpt lists 33,863,689 shares outstanding as of 06/10/2026. This figure is presented as a baseline number in the filing content and tied to that date in the excerpt.

Are gross proceeds shown for each sale in VICR's Form 144 excerpt?
Yes, each trade entry in the excerpt includes a gross dollar amount; for example, $5,599,845.00 for the 20,000-share sale on 06/09/2026, with similar dollar figures provided for other dated trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Accepted by SEC EDGAR

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR

Keep reading

More on VICR

All VICR news

Trending in the feed

LQDA
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH Open the live feed